NeoDynamics

NeoDynamics AB today announced the appointment of Matilda Salén as its new Chief Executive Officer. She will replace Anna Eriksrud, who earlier this spring announced her intention to retire from NeoDynamics. Matilda has a Bachelor’s degree in Cognitive Neuroscience from Harvard University and has since been working as a management consultant in the U.S. and Sweden. She has specialized in M&A and growth strategy in the life science/MedTech sectors, most recently at Arthur D. Little in Stockholm. Since January 2024, Matilda has been working as a consultant for NeoDynamics, preparing the company both for increased sales but also getting the company ready for a sale to or partnership with a larger industry player.

“I am very much looking forward to helping take NeoDynamics and the NeoNavia-system to the next level. It is an impressive product granting better biopsy experiences for both patients and physicians. Despite a financially challenging journey during the long years of product development, the now complete NeoNavia system is the platform we need to achieve sales, excite customers and prove the value of the product and the company. I will be focused on working with the NeoDynamics team to optimize business performance as well as finding industry players who could strategically fit NeoNavia into their portfolio”, says Matilda Salén.

“We are happy that Matilda has agreed to join NeoDynamics. With her experience in M&A and the MedTech sector from Arthur D. Little we think that she is well equipped to find an industry player that quickly can take the NeoNavia-system to the women of the world as quickly as possible”, says Ingrid Salén Chairman of the board of NeoDynamics.

For further information, please contact:
Ingrid Salén, Chairman NeoDynamics AB, phone +46 657 1515 or e-mail Ingrid.salen@rentability.se
Matilda Salén, CEO NeoDynamics AB, phone +46-768 436574 or e-mail matilda.salen@neodynamics.com

About NeoDynamics
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in USA during 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.

About NeoNavia
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.

About Karolinska Institute
The Karolinska Institute is consistently ranked amongst the world's best medical schools, ranking 6th worldwide for medicine in 2021. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine.